Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
21.20
+8.42 (65.88%)
At close: Mar 6, 2026, 4:00 PM EST
21.16
-0.04 (-0.19%)
After-hours: Mar 6, 2026, 7:58 PM EST
DAWN Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 158.18 | 131.16 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 20.60% | - | - | - | - | Upgrade
|
| Cost of Revenue | 17.21 | 5.28 | - | - | - | Upgrade
|
| Gross Profit | 140.97 | 125.88 | - | - | - | Upgrade
|
| Selling, General & Admin | 120.59 | 115.45 | 75.54 | 61.29 | 29.16 | Upgrade
|
| Research & Development | 148.14 | 222.7 | 130.52 | 85.62 | 43.58 | Upgrade
|
| Operating Expenses | 268.72 | 338.15 | 206.06 | 146.91 | 72.74 | Upgrade
|
| Operating Income | -127.75 | -212.27 | -206.06 | -146.91 | -72.74 | Upgrade
|
| Interest & Investment Income | 18.47 | 19.7 | 17.19 | 4.75 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.02 | 109.22 | -0.04 | -0.02 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -109.3 | -83.35 | -188.92 | -142.18 | -72.75 | Upgrade
|
| Other Unusual Items | - | -5 | - | - | - | Upgrade
|
| Pretax Income | -109.3 | -88.35 | -188.92 | -142.18 | -72.75 | Upgrade
|
| Income Tax Expense | -1.98 | 7.14 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -107.32 | -95.5 | -188.92 | -142.18 | -72.75 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 2.11 | Upgrade
|
| Net Income | -107.32 | -95.5 | -188.92 | -142.18 | -70.65 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 99.99 | Upgrade
|
| Net Income to Common | -107.32 | -95.5 | -188.92 | -142.18 | -170.64 | Upgrade
|
| Shares Outstanding (Basic) | 103 | 93 | 80 | 65 | 37 | Upgrade
|
| Shares Outstanding (Diluted) | 103 | 93 | 80 | 65 | 37 | Upgrade
|
| Shares Change (YoY) | 10.70% | 16.87% | 21.85% | 77.13% | 568.42% | Upgrade
|
| EPS (Basic) | -1.04 | -1.02 | -2.37 | -2.17 | -4.62 | Upgrade
|
| EPS (Diluted) | -1.04 | -1.02 | -2.37 | -2.17 | -4.62 | Upgrade
|
| Free Cash Flow | -104.08 | -80.28 | -147.08 | -109.9 | -48.54 | Upgrade
|
| Free Cash Flow Per Share | -1.01 | -0.86 | -1.84 | -1.68 | -1.31 | Upgrade
|
| Gross Margin | 89.12% | 95.97% | - | - | - | Upgrade
|
| Operating Margin | -80.76% | -161.84% | - | - | - | Upgrade
|
| Profit Margin | -67.85% | -72.81% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -65.80% | -61.21% | - | - | - | Upgrade
|
| EBITDA | -124.27 | -210.71 | -206.03 | -146.85 | -72.72 | Upgrade
|
| EBITDA Margin | -78.56% | -160.65% | - | - | - | Upgrade
|
| D&A For EBITDA | 3.48 | 1.56 | 0.04 | 0.06 | 0.02 | Upgrade
|
| EBIT | -127.75 | -212.27 | -206.06 | -146.91 | -72.74 | Upgrade
|
| EBIT Margin | -80.76% | -161.84% | - | - | - | Upgrade
|
| Revenue as Reported | 158.18 | 131.16 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.